Hormonal
A reduced ratio of branched-chain amino acids (BCAA) to aromatic amino acids (AAA) in plasma is a specific metabolic signature of PCOS that is independent of obesity and insulin resistance, distinguishing it from type 2 diabetes profiles.
Your amino acid profile, specifically the balance between BCAA and AAA, is a unique fingerprint of PCOS. This helps doctors distinguish your condition from type 2 diabetes, even if you have insulin resistance. This distinction is important for tailoring the right treatment strategy for your specific metabolic needs.
Furthermore, the ratio of branched-chain amino acid to aromatic amino acid concentrations (BCAA/AAA) in PCOS plasma was significantly reduced in PCOS patients and was insusceptible to obesity and insulin sensitivity.
Why this rating
Statistically significant findings across multiple PCOS phenotypes using robust metabolomic analysis.
Source
Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis
Yue Zhao et al. · BMC Medicine · 2012
DOI 10.1186/1741-7015-10-153
More from this paper
- Women with polycystic ovary syndrome (PCOS) exhibit a distinct metabolic profile characterized by elevated lactate, long-chain fatty acids, and specific amino acids (valine, leucine, serine, threonine, phenylalanine, tyrosine, ornithine), alongside reduced glucose, glycine, and proline, which serves as a biomarker for insulin resistance and diabetes risk.Good
- Ovulatory dysfunction in PCOS is associated with elevated levels of serine, threonine, phenylalanine, tyrosine, and ornithine, suggesting that increased ovarian uptake of these amino acids contributes to anovulation.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →